LakeShore Biopharma Co., Ltd (LSB)
NASDAQ: LSB · Real-Time Price · USD
0.8050
-0.0255 (-3.07%)
At close: Sep 15, 2025, 4:00 PM EDT
0.7889
-0.0161 (-2.00%)
After-hours: Sep 15, 2025, 4:39 PM EDT
LakeShore Biopharma Revenue
In the fiscal year ending March 31, 2025, LakeShore Biopharma had annual revenue of 614.96M CNY with 7.24% growth. LakeShore Biopharma had revenue of 135.35M in the quarter ending March 31, 2024, with 27.67% growth.
Revenue (ttm)
614.96M CNY
Revenue Growth
-6.54%
P/S Ratio
0.19
Revenue / Employee
1,073,231 CNY
Employees
573
Market Cap
33.18M undefined
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 614.96M | 41.54M | 7.24% |
Mar 31, 2024 | 573.42M | -113.78M | -16.56% |
Mar 31, 2023 | 687.20M | 184.25M | 36.63% |
Mar 31, 2022 | 502.95M | 245.93M | 95.69% |
Mar 31, 2021 | 257.02M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LSB News
- 3 days ago - LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq - PRNewsWire
- 5 days ago - LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee - PRNewsWire
- 18 days ago - LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee - PRNewsWire
- 4 weeks ago - LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company - PRNewsWire
- 6 weeks ago - LakeShore Biopharma Announces Fiscal Year 2025 Financial Results - PRNewsWire
- 2 months ago - LakeShore Biopharma Announces US$15 Million Private Placement Financing - PRNewsWire
- 5 months ago - LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell) - PRNewsWire
- 9 months ago - LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance - PRNewsWire